InNexus Biotechnology Files Patent for Novel AMD Therapeutic

June 2011
Biomedical Market Newsletter;6/19/2011, p546
The article reports that biopharmaceutical company Innexus Biotechnology Inc. has filed for patent protection regarding its Age-related Macular Degeneration (AMD) and eye disorder antibody product. It mentions that the product of the company was develop as topical therapy or eye drop for several eye disorders such as diabetic retinopathy and AMD. Jeff Morhet of InNexus states that they are confident that their product will play an important role in pharmaceutical market.


Related Articles

  • InNexus Biotechnology announces development of new colorectal cancer drug.  // PharmaWatch: Cancer;Dec2008, Vol. 7 Issue 12, p17 

    The article focuses on the development of a new colorectal cancer drug by InNexus Biotechnology Inc. in 2008. The company has revealed the development of DXL1218 from its DXL platform technology for the prospective treatment of colorectal cancer. According to Jeff Morhet, chief executive officer...

  • New Drug Device to Treat Diabetes-Related Vision Loss.  // Review of Ophthalmology;Aug2011, Vol. 18 Issue 8, p4 

    The article discusses the development of a new drug device to treat retinal damage caused by diabetes. Diabetic retinopathy, which is caused by the unwanted growth of capillary cells in the retina, is noted to be the leading cause of vision loss among patients with diabetes. The development of...

  • Eyeing up the AMD and DR market.  // PharmacoEconomics & Outcomes News;7/16/2011, Issue 633, p11 

    The article focuses on the possible growth of the market for age-related macular degeneration (AMD) and diabetic retinopathy (DR) drugs from 3,173 million U.S. dollars in 2010 to 5,084 million dollars by 2014, according to a visiongain report released on July 11, 2011.

  • A glimpse into this issue. Natarajan, Sundaram // Indian Journal of Ophthalmology;Dec2015, Vol. 63 Issue 12, p879 

    An introduction is presented in which the editor discusses various reports within the issue on topics including diabetic retinopathy (DR), macular degeneration (AMD), and the effect of the chemical compound lanosterol on human cataract nucleus.

  • INNEXUS BIOTECHNOLOGY GETS PATENT GRANTS IN EUROPE.  // Worldwide Biotech;Dec2008, Vol. 20 Issue 12, p8 

    The article reports on the patent grants received by InNexus Biotechnology Inc. in several countries in Europe which further expanded the patent protections of its DXL technology in Europe. The patents are titled Method of Affinity Cross-Linking Biologically Active, Immunogenic Peptides to...

  • European patents for DXL technology.  // Medical Device Daily;10/31/2008, Vol. 12 Issue 213, p8 

    The article reports that patent grants were given to InNexus Biotechnology for its next generation of monoclonal antibodies using its Dynamic Cross Linking (DXL) technology. The patents titled "Method of Affinity Cross-Linking Biologically Active, Immunogenic Peptides to Antibodies" were granted...

  • Partnership will deliver advances in cell therapy in ophthalmology.  // Biomedical Market Newsletter;10/24/2011, Vol. 21, p367 

    The article reports on the clinical and commercial supply agreement between iScience Interventional and Johnson & Johnson Pharmaceutical Research and Development LLC (J&JPRD), in which iScience will supply iTrack 275 microcatheters for J&PRD's cell therapy CNT02476 delivery for retinal...

  • CNV Therapy Doubted.  // Review of Ophthalmology;Mar2000, Vol. 7 Issue 3, p81 

    Examines the role of radiation therapy in subfoveal choroidal neovascularization secondary to age-related macular degeneration. Changes in the visual acuity of the patients; Radiation-associated with choroidal neovasculopathy noted in patients receiving external beam radiation; Chances for...

  • Fluorescein angiography still plays a crucial role in evaluation, management.  // Ocular Surgery News Europe;Feb2012, Vol. 23 Issue 2, p14 

    The article reports on eye specialist Barbara Blodi, MD’s research on the role of fluorescein angiography in the baseline evaluation of neovascular age-related macular degeneration and the long-term management of diabetic retinopathy and retinal vein occlusion.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics